Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

50%

3 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 3

3(50.0%)

Phase 2

2(33.3%)

Phase 1

1(16.7%)

6Total

Phase 3(3)

Phase 2(2)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT04902781Phase 2Completed

Clinical Benefit, Safety, PK and PD Study of AT-007 in Pediatric Subjects With Classic Galactosemia

Role: lead

NCT07191912Phase 3Not Yet Recruiting

Confirmatory Study of Govorestat in CMT-SORD

Role: lead

NCT05397665Phase 2Active Not Recruiting

Pharmacodynamic EffIcacy and Clinical Benefit of AT 007 in Patients With Sorbitol Dehydrogenase (SORD) Deficiency

Role: lead

NCT04117711Phase 1Completed

Safety and Pharmacokinetics of AT-007 in Healthy Subjects and in Adult Subjects With Classic Galactosemia

Role: lead

NCT04083339Phase 3Active Not Recruiting

Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy

Role: lead

NCT05418829Phase 3Unknown

AT-007 in Adult Subjects With Classic Galactosemia (CG)

Role: lead

All 6 trials loaded